Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on RAPP. Rapport Therapeutics, Inc.’s share was trading at $38.26 as of June 15th. RAPP’s trailing P/E was 23.78 according to Yahoo Finance.
Pressmaster/Shutterstock.com
Rapport Therapeutics (RAPP) is a Boston-based clinical-stage biotechnology company developing precision therapies for serious neurological and...
